Search Results | Blood | American Society of Hematology

1-20 of 125

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Blood (2022) 139 (17): 2706–2711.

DOI: https://doi.org/10.1182/blood.2021014648

Published: 2022

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

DOI: https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Blood (2021) 138 (Supplement 1): 471.

DOI: https://doi.org/10.1182/blood-2021-149332

Published: 2021

Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney

Blood (2021) 138 (4): 318–330.

DOI: https://doi.org/10.1182/blood.2020008221

Published: 2021

Includes: Supplemental data

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

DOI: https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

Tim Sauer, MD, Kathan Parikh, Sandhya Sharma, Bilal Omer, MD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD

Blood (2019) 134 (Supplement_1): 1932.

DOI: https://doi.org/10.1182/blood-2019-125534

Published: 2019

Journal Articles

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Lauren P. McLaughlin, Rayne Rouce, Stephen Gottschalk, Vicky Torrano, George Carrum, Meng-Fen Wu, Fahmida Hoq, Bambi Grilley, Andrea M. Marcogliese, Patrick J. Hanley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard

Blood (2018) 132 (22): 2351–2361.

DOI: https://doi.org/10.1182/blood-2018-07-863654

Published: 2018

Journal Articles

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

George Carrum, MD, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Ayumi Watanabe, Manik Kuvalekar, Mrinalini Bilgi, Rammurti Kamble, MD, Carlos A. Ramos, MD, Rayne Rouce, MD, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Cliona M. Rooney, PhD, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1685.

DOI: https://doi.org/10.1182/blood-2018-99-113140

Published: 2018

Journal Articles

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Carlos A. Ramos, MD, Mrinalini Bilgi, Claudia P. Gerken, Olga Dakhova, Zhuyong Mei, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Cliona M. Rooney, PhD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Helen E. Heslop, MDDSc, Malcolm K. Brenner, MD PhD

Blood (2018) 132 (Supplement 1): 680.

DOI: https://doi.org/10.1182/blood-2018-99-111202

Published: 2018

Journal Articles

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4073.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4073.4073

Published: 2017

Journal Articles

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 4484.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4484.4484

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

DOI: https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Fast and Efficient Gene Editing in Human Hematopoietic Cells

Michael C Gundry, BS, Lorenzo Brunetti, MD, Dimitrios Laurin Wagner, Joanne Hsu, BS, Mireya Paulina Velasquez, MD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD, Margaret Goodell, PhD

Blood (2016) 128 (22): 4704.

DOI: https://doi.org/10.1182/blood.V128.22.4704.4704

Published: 2016

Journal Articles

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Ifigeneia Tzannou, MD, Anastasia Papadopoulou, PhD, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Swati Naik, MD, Caridad Martinez, MD, Kathryn S. Leung, Ghadir S. Sasa, MD, Robert A. Krance, MD, George Carrum, MD, Carlos A. Ramos, MD, Bambi Grilley, Malcolm K. Brenner, MD PhD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Ann M. Leen, PhD, Bilal Omer, MD

Blood (2016) 128 (22): 501.

DOI: https://doi.org/10.1182/blood.V128.22.501.501

Published: 2016

Journal Articles

CAR T Cells Targeted with a High Affinity Scfv Against the HCMV Glycoprotein Gb As Adoptive T Cell Therapy after Hematopoietic Stem Cell Transplantation

Renata Stripecke, PhD, Laura Gerasch, Sebastian Theobald, Bala Sai Sundarasetty, PhD, Maksim Mamonkin, PhD, Thomas Shum, BS, Cliona M. Rooney, PhD

Blood (2016) 128 (22): 5721.

DOI: https://doi.org/10.1182/blood.V128.22.5721.5721

Published: 2016

Journal Articles

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Diogo Gomes da Silva, Malini Mukherjee, Madhuwanti Srinivasan, Olga Dakhova, PhD, Hao Liu, PhD, Bambi Grilley, Adrian P. Gee, PhD, Sattva S. Neelapu, MD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Barbara Savoldo, MD PhD, Gianpietro Dotti, MD, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD, Carlos A. Ramos, MD

Blood (2016) 128 (22): 1851.

DOI: https://doi.org/10.1182/blood.V128.22.1851.1851

Published: 2016

Journal Articles

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Rayne H. Rouce, MD, Birju Mehta, Sandhya Sharma, Serena Kimi Perna, MD, Benjamin Shin, Vicky Torrano, Fnu Spoorthi, Natalia Lapteva, PhD, Catherine M. Bollard, MD, Adrian P. Gee, PhD, Carlos A. Ramos, MD, Shannon Inman, Karen L. Hodgkin, Kurt C. Gunter, MD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD, Cliona M. Rooney, PhD

Blood (2016) 128 (22): 2990.

DOI: https://doi.org/10.1182/blood.V128.22.2990.2990

Published: 2016

Journal Articles

Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens

Ann Leen, PhD, Ifigeneia Tzannou, MD, Munu Bilgi, Hao Liu, PhD, Juan F Vera, MD, Ulrike Gerdemann, MD, Rammurti T Kamble, MD, Carlos A. Ramos, MD, Bambi Grilley, RPh, Adrian P. Gee, PhD, Catherine M. Bollard, MD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD, Cliona M. Rooney, PhD, George Carrum, MD

Blood (2015) 126 (23): 186.

DOI: https://doi.org/10.1182/blood.V126.23.186.186

Published: 2015

Journal Articles

Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Ifigeneia Tzannou, MD, Bilal Omer, MD, Anastasia Papadopoulou, PhD, Ulrike Gerdemann, MD, Colton Smith, PhD, Adrian P. Gee, PhD, Bambi J Grilley, Malcolm K. Brenner, MB, PhD FRCP, FRCPath, Catherine M. Bollard, MD, Ann M. Leen, PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 1926.

DOI: https://doi.org/10.1182/blood.V126.23.1926.1926

Published: 2015

Journal Articles

Safety of Multiple Doses of CAR T Cells

Rayne H. Rouce, MD, Kristen Fousek, Nabil Ahmed, MD, Stephen Gottschalk, MD, Barbara Savoldo, MD, Gianpietro Dotti, MD, Carlos A. Ramos, MD, Chrystal Louis, MD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 4425.

DOI: https://doi.org/10.1182/blood.V126.23.4425.4425

Published: 2015

2 3 4 5

NARROW

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Fast and Efficient Gene Editing in Human Hematopoietic Cells

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

CAR T Cells Targeted with a High Affinity Scfv Against the HCMV Glycoprotein Gb As Adoptive T Cell Therapy after Hematopoietic Stem Cell Transplantation

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens

Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Safety of Multiple Doses of CAR T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only